Navigation Links
Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
Date:5/15/2008

MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the Seventh Annual JMP Securities Research Conference on Monday, May 19, 2008 at 11:30 a.m. Eastern Time and at the Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 2:00 p.m. Eastern Time.

The JMP presentation will be webcast from The Ritz-Carlton Hotel in San Francisco. To access the live presentation via the Web, please go to the Investor Relations tab at http://www.alexza.com or at http://www.wsw.com/webcast/jmp6/alxa/.

The Citi Investment will be webcast from the Hilton New York Hotel in San New York. To access the live presentation via the Web, please go to the Investor Relations tab at http://www.alexza.com or at http://www.veracast.com/webcasts/citigroup/healthcare08/31112361.cfm.

A replay of each webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ardea Biosciences Announces Upcoming Corporate Meetings
2. Direct Reliefs Corporate Partners Key to Aiding Cyclone Victims
3. Aflac Incorporated to Webcast 2008 Financial Analysts Briefing
4. Health Care Corporate Compliance Certificate Program to Be Offered at Hamline University School of Laws Health Law Institute
5. GSK Announces Changes to Corporate Executive Team
6. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
7. Government and Corporate Support Together Help Africans Battling Malaria, AIDS
8. Accuray Incorporateds CEO to Present at Morgan Stanley 2008 Global Healthcare Unplugged Conference
9. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
10. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
11. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells ... Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, ... moved to NYC when she was three. At six, they moved to Dayton, Ohio, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology: